Why the study?
Does a bioresorbable scaffold reduce target-vessel failure compared to a metallic stent in patients undergoing routine PCI?
Does a bioresorbable scaffold reduce target-vessel failure compared to a metallic stent in patients undergoing routine PCI?
In routine PCI, bioresorbable scaffolds do not improve target-vessel failure rates compared to metallic stents and are associated with an increased risk of device thrombosis at 2 years.
Bioresorbable scaffolds confer no target-vessel failure benefit versus metallic stents in routine PCI; challenges expectations of improved outcomes and supports metallic stent preference.
In this preliminary report of a trial involving patients undergoing PCI, there was no significant difference in the rate of target-vessel failure between the patients who received a bioresorbable scaffold and the patients who received a metallic stent. The bioresorbable scaffold was associated with a higher incidence of device thrombosis than the metallic stent through 2 years of follow-up. (Funded by Abbott Vascular; AIDA ClinicalTrials.gov number, NCT01858077 .).
No takes yet. Share an insight, caveat, or question.
Wykrzykowska et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: